^
    Back
    Association details:
    Biomarker:ALK mutation
    Cancer:Neuroblastoma
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    batoprotafib (TNO155) (PTPN11 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res Commun
    Title:

    SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma

    Published date:
    12/27/2023
    Excerpt:
    Here, we have assessed the efficacy of the SHP2 inhibitor TNO155 alone and in combination with the ALK-TKIs crizotinib, ceritinib, or lorlatinib for the treatment of ALK-driven neuroblastoma using in vitro and in vivo models….Moreover, treatment with TNO155 and ALK-TKIs synergistically reduced cell growth and promoted inactivation of ALK and MAPK signaling in ALK-mutant neuroblastoma cells.
    DOI:
    https://doi.org/10.1158/2767-9764.CRC-23-0234